Promyelocytic leukemia (PML), is a gene that encodes for a transcription factor and tumor suppressor protein (Gene 2013a). PML is involved in rearrangements observed in AML, particularly APL (acute promyelocytic leukemia).

Retinoic acid receptor, alpha (RARA) is a gene that encodes for a nuclear retinoic acid receptor, a transcription regulating protein (Gene 2013b). In cancer, rearrangements involving RARA have been observed in AML and APL. Its role is also being investigated in gastric and other cancers.

The PML-RARA fusion has been observed in most cases of APL.

Contributors: Adam Seegmiller, M.D., Ph.D., Madan Jagasia, M.B.B.S., M.S.

Suggested Citation: Seegmiller, A., Jagasia, M. 2013. PML-RARA. My Cancer Genome (Updated June 2013)

Modified: June 4, 2013

Disclaimer: The information presented at is compiled from sources believed to be reliable. Extensive efforts have been made to make this information as accurate and as up-to-date as possible. However, the accuracy and completeness of this information cannot be guaranteed. Despite our best efforts, this information may contain typographical errors and omissions. The contents are to be used only as a guide, and health care providers should employ sound clinical judgment in interpreting this information for individual patient care.